SURPASS-CVOT and the GLP-1 ceiling question

SURPASS-CVOT, the largest head-to-head cardiovascular outcomes trial in the incretin class, found that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events (MACE) in patients with type-2 diabetes and established atherosclerotic cardiovascular disease^[1]. The primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group over a median four-year follow-up (HR 0.92; 95.3% CI 0.83 to 1.01). Noninferiority was confirmed (p = 0.003). Superiority was not (p = 0.09).

A June 2026 commentary in the Journal of the American College of Cardiology frames this result as a "cardio-metabolic paradox"^[2]. Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered substantially larger improvements in weight (11.6% vs 4.5%), HbA1c (1.66 vs 0.88 percentage points), and all-cause mortality (HR 0.84) than dulaglutide, a GLP-1-only agonist. Yet on the hardest cardiovascular endpoint, the two drugs landed in the same statistical neighbourhood. The question the commentary raises: why didn't the extra metabolic benefit translate into clear cardiovascular superiority?

The GLP-1 ceiling hypothesis

One explanation, which the JACC authors call the "GLP-1 ceiling," is that once a GLP-1 receptor agonist reaches a certain level of cardiovascular protection, additional GLP-1 receptor activation cannot push the MACE curve much further. Dulaglutide already demonstrated cardiovascular noninferiority versus placebo in the REWIND trial^[3]. If the GLP-1 pathway has a ceiling on how far it can reduce cardiac events, then even a potent dual agonist like tirzepatide may not break through it by adding more GLP-1 signalling.

This does not mean the GLP-1 component is unimportant. It means the incremental CV gain from maximal GLP-1 activation may be small relative to what a proven GLP-1 agonist already delivers. The MACE difference between 12.2% and 13.1% is real but modest, and the trial was not powered to detect a difference of that size with statistical confidence. The 13,299 patients enrolled across 640 sites in 30 countries were randomized to tirzepatide (escalated up to 15 mg weekly) or dulaglutide (1.5 mg weekly), with a mean age of 64 years and a mean diabetes duration of nearly 15 years.

The GIP dividend

The second half of the commentary's argument is that GIP receptor activation contributes something different: metabolic and renal benefits that sit outside the classical MACE composite. In SURPASS-CVOT, tirzepatide produced significantly greater reductions in body weight and glycaemic markers. It also showed a nominally lower rate of all-cause mortality, a finding driven by noncardiovascular death rather than cardiovascular death. The JACC authors suggest this pattern is consistent with GIP acting on adipocyte metabolism, renal function, and possibly inflammatory pathways that do not show up in a three-point MACE endpoint.

This framing reframes what "benefit" means. If tirzepatide's value over a GLP-1-only drug is not primarily cardiac but metabolic and renal, then trials designed around MACE composites will undercount the clinical difference. The trial design choice to use an active comparator (dulaglutide) rather than placebo makes this harder to parse, because the control arm itself had proven cardiovascular benefit. The ACC's journal scan of the trial notes that the imputed-placebo methodology accepted by both the FDA and EMA was a first for the cardiometabolic field^[4].

What this does not settle

The commentary is an editorial, not new data. It offers a framework for reading the SURPASS-CVOT numbers, not a settled answer. Several questions remain open. First, whether the all-cause mortality signal (HR 0.84) will hold in subsequent analyses or in other tirzepatide cardiovascular trials. Second, whether the renal benefits are clinically meaningful at the individual patient level, or an artefact of the bigger metabolic shift. Third, whether GIP receptor activation carries long-term risks that are not yet visible in a four-year trial. The secondary endpoint comparisons in SURPASS-CVOT were not adjusted for multiplicity, which means they are hypothesis-generating, not confirmatory. Gastrointestinal adverse events were also more common with tirzepatide, and discontinuation for adverse events ran higher in the tirzepatide arm (13.2% vs 10.1%), a safety signal that tempers the metabolic gains.

Where this sits for readers

For anyone following the incretin class, the practical takeaway is that tirzepatide's cardiovascular safety versus a proven GLP-1 agonist is now established in a large, long trial. The superiority question remains open, and the answer may depend on which outcomes you measure. The JACC commentary is useful because it names the problem clearly: a dual agonist that wins on metabolism but draws on MACE forces the field to reconsider what "better" means in cardiovascular outcomes research. For country-specific regulatory status, see the tirzepatide regulation pages.